News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?
Amol Akhade/hiranandanihospital.org
Apr 16, 2025, 17:55

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:

“LET’S PLAY DEVIL’S ADVOCATE:

Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer? Tannock et al. JCO_ASCO argue –

Modest iDFS, no OS benefit ( yet ) , high toxicity and censoring bias.

I broke it down—with counterarguments .

Do Check this out.”

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor

Authors: Ian F. Tannock, Qamar J. Khan, and Tito Fojo 

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

More posts featuring Amol Akhade.

Amol Akhade Breast Cancer cancer cancer treatment Ian F. Tannock OncoDaily Oncology Qamar J. Khan Tito Fojo
Special Coverage
Blog
Jun 19, 2025, 17:36
ESTRO Introduces KAYAC+ to Advance Radiation Therapy For Adolescents And Young Adults With Cancer
Blog
Jun 19, 2025, 17:26
XVII CCI LATAM Conference Was a Celebration Of a Growing Community, Unity, and Hope - Childhood Cancer International
Blog
Jun 19, 2025, 17:07
Join The AI For Everyone, Everywhere, Let’s talk about Large Language Models Meeting - SIOP
Blog
Jun 19, 2025, 16:57
David Planchard: We Need to Work Together to Develop The Wave of New Treatments That Is Coming For Our Patients
Blog
Jun 19, 2025, 16:21
Neeraj Agarwal: Poor Outcomes with SOC in mHSPC Prostate Cancer Patients With HRR Mutation
Blog
Jun 19, 2025, 16:12
World Kidney Cancer Day 2025: Uniting for Progress in the Fight Against Renal Cell Carcinoma
Blog
Jun 19, 2025, 16:01
IARC Marks World Kidney Cancer Day with New Video and Project Highlights
Science
Jun 19, 2025, 15:50
Alexey Kulikov Shared An Article on Cancer Vaccines and The Future of Immunotherapy
Opinion
Jun 19, 2025, 15:47
Mostafa Faisal: Primary Refractory AML and Allo-HCT - A 10-Year Retrospective Study from Japan
Blog
Jun 19, 2025, 15:36
Amol Akhade: KEYNOTE-689 - A Turning Point in Resectable HNSCC - Or a Cautious Step Forward?
Drugs
Jun 19, 2025, 15:30
Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma
Blog
Jun 19, 2025, 15:15
Antonio Jimenez Jimenez Shared Findings from the Multicenter ACCESS trial, Supported by CIBMTR and NMDP